A 40% reduction in the risk of cognitive failure or death is a number that should retire a decades-old treatment reflex. Results from the phase III SWOG S1827 MAVERICK trial, presented at the IASLC 2026 World Conference on Lung Cancer, show that MRI surveillance alone outperformed MRI surveillance plus prophylactic cranial irradiation (PCI) on cognitive failure-free survival in patients with small-cell lung cancer (HR 0.60; 90% CI 0.46–0.78; p=0.001). The 304-patient international trial enrolled both limited-stage and extensive-stage SCLC patients who had completed initial therapy with no brain metastases at baseline, then followed them with brain MRIs every three months in year one and every six months in year two.
The cognitive toll of PCI is where the trial’s findings are sharpest. Grade 3–5 adverse events occurred in fewer than 1% of patients on MRI surveillance alone, compared with nearly 8% in the MRI plus PCI group (0.8% vs. 7.9%; p=0.004), and one patient in the PCI arm died from encephalopathy. PCI has been used after initial SCLC therapy since pre-MRI era trials showed brain metastasis reduction and an overall survival benefit, with the most-cited evidence coming from a 1999 meta-analysis of seven randomized trials conducted between 1977 and 1994. MAVERICK was built on the question of whether modern MRI is sensitive enough to detect early metastases and allow prompt salvage treatment, making the cognitive cost of prophylactic radiation unnecessary.
On survival, the trial does not yet deliver a clean answer. A preliminary analysis after 128 deaths showed no meaningful difference in overall survival between arms (HR 0.90; 90% CI 0.67–1.20), and brain metastasis-free survival was also statistically similar. The final overall survival analysis is planned after 190 deaths, so that question stays open. Notably, the cognitive failure-free survival benefit held across both disease stages and regardless of whether patients had received immunotherapy, a detail that matters given the 2024 FDA approval of durvalumab for limited-stage SCLC and the growing proportion of patients now treated with checkpoint inhibitors as part of initial therapy.
Chad Rusthoven of the University of Colorado School of Medicine, who presented the data, called MRI surveillance alone the new standard of care for SCLC patients. The practical consequence: oncology teams can remove PCI from the post-treatment algorithm without a survival penalty at current follow-up, reducing a source of serious toxicity that has been widely accepted as an unavoidable tradeoff. The mature overall survival data, when it arrives after 190 deaths, will determine whether that position holds permanently.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
